New drug combo aims to boost growth in kids with dwarfism
NCT ID NCT06433557
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether giving two weekly injections together can improve growth in children aged 2 to 11 with achondroplasia, a common cause of dwarfism. The drugs, navepegritide and lonapegsomatropin, are designed to increase height. The trial will measure growth rate and monitor side effects over 156 weeks. It involves 22 children and is not yet recruiting.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACHONDROPLASIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Ascendis Pharma Investigational Site
Copenhagen, 2100, Denmark
-
Ascendis Pharma Investigational Site
Dublin, D01 YC76, Ireland
-
Ascendis Pharma Investigational Site
London, W1W 5AH, United Kingdom